問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Division of Radiation Therapy

Division of Hematology & Oncology

更新時間：2023-09-19

趙毅Chao, Yee
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 11 個月

Recruiting Trial

65Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙毅

List

194Cases

2016-05-01 - 2020-04-30

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Pembrolizumab (MK-3475) /KEYTRUDA

Participate Sites
7Sites

Terminated6Sites

邱昌芳
China Medical University Hospital-Taipei

未分科

林錫銘
Linkou Chang Gung Medical Foundation

Digestive System Department

2009-12-01 - 2012-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2015-09-01 - 2018-12-31

Phase II

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Durvalumab (MEDI4736), Tremelimumab

Participate Sites
3Sites

Terminated3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2010-07-01 - 2011-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-07-01 - 2011-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-09-01 - 2009-09-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-01-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2018-07-01 - 2020-12-31

Phase II

Randomized, controlled, open label, clinical trial for - adagloxad simolenin/OBI-821 in combination with TACE therapy in hepatocellular carcinoma patients with GALNT14-rs9679162-non-TT genotype

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Adagloxad simolenin (OBI-822)/OBI-821

Participate Sites
5Sites

Terminated4Sites

2017-04-05 - 2018-09-27

Phase II/III

A TWO-PART PHASE 2/ 3 MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS MFOLFOX6 VERSUS PLACEBO PLUS MFOLFOX6 IN SUBJECTS WITH HER1/ HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER WITHOUT PRIOR EXPOSURE TO SYSTEMIC THERAPY

  • Condition/Disease

    HER1/ HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER

  • Test Drug

    Varlitinib

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

1 11 12 13 14 15 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB